

ALTERNATIVE MEDICINE REPORTS

Supplement to Alternative Medicine Alert

American Health Consultants Home Page—<http://www.ahcpub.com>

CME for Physicians—<http://www.cmeweb.com>

Alternative Therapies for Benign Prostatic Hyperplasia

By *Cydney E. McQueen, PharmD,*
and *Kelly M. Shields, PharmD*

BENIGN PROSTATIC HYPERPLASIA (BPH) IS A NON-CANCEROUS INCREASE IN THE TISSUE mass of the prostate, the muscular gland that produces seminal fluid. BPH is one of the most common medical conditions affecting older men. It may be diagnosed because of urinary symptoms, or identified when a large prostate is found during a routine screening rectal exam. Many men simply have a slow worsening of symptoms throughout their lifetimes, usually beginning in their 50s. Sub-clinical disease is very common: Approximately 80% of men older than age 60 will have histological changes indicative of BPH upon biopsy; by age 85, this percentage rises to 90%.¹ Some of these patients have severe disease progression, which can lead to incontinence, formation of calculi, frequent urinary tract infections, or permanent urinary tract damage.

Despite the possibility of progression and the bothersome symptoms, many men—perhaps half of those with the condition—never seek medical advice or treatment for BPH symptoms, even when those symptoms are severe enough to warrant surgical intervention.² Patients may believe that urinary symptoms are part of the normal aging process, that nothing that can be done, or that the available treatments have unacceptable side effects.

Etiology/Pathophysiology

BPH is related to age-associated changes in the body's hormone levels.³ Although the clinical ramifications of these hormone changes are not completely characterized, it is known that the levels of serum testosterone decrease while dihydrotestosterone (DHT), the principle androgen responsible for prostatic growth,^{4,5} accumulates. Until recently, it was believed that estradiol, converted from testosterone via the aromatase pathway, was implicated in initiating hyperplasia in the stroma and epithelium of the prostate.⁴ That now seems unlikely.⁶

Factors that may accelerate disease progression are not well enumerated. Diet is one factor that has been implicated in the development of BPH. A Western diet characterized by high fat intake appears to be linked to earlier onset of BPH.^{7,8} One study indicated that low intake of vegetables is positively associated with BPH risk,⁹ whereas another drew a correlation between alcohol consumption (more than 25 ounces/month) and BPH risk.¹⁰ However, each of these studies had limitations and did not demonstrate a clear, direct correlation. Symptoms may be worsened by various factors such as evening intake of liquids, decongestant use, or caffeine, alcohol, or spicy food intake.

INSIDE

Symptoms of BPH . . . page 27

*American Urological
Association Urinary
Symptom Index
for Prostatism page 28*

EXECUTIVE EDITOR

John La Puma, MD, FACP
Director, CHEF Clinic (Cooking, Healthy
Eating & Fitness)
Professor of Nutrition, Kendall College
Alexian Brothers Medical Center
Elk Grove Village, IL

ALTERNATIVE MEDICINE REPORTS EDITOR

David Schiedermayer, MD, FACP
Professor of Medicine
Medical College of Wisconsin
Milwaukee, MI

EDITORIAL ADVISORY BOARD

Judith Balk, MD, FACOG
Assistant Research Professor
University of Pittsburgh
Pittsburgh, PA

E-P. Barrette, MD, FACP

Assistant in Medicine
Massachusetts General Hospital
Boston, MA

Michael Cirigliano, MD, FACP

Assistant Professor of Medicine
University of Pennsylvania School of
Medicine
Philadelphia, PA

Dennis deLeon, MD, FAAFP

Director, Family Medicine Residency
Loma Linda University School of
Medicine, Loma Linda, CA

Barak Gaster, MD

Assistant Professor of Medicine
University of Washington School of
Medicine, Seattle, WA

Matthew Sorrentino, MD, FACC

Associate Professor of Medicine
The University of Chicago Pritzker School
of Medicine
Chicago, IL

Symptoms

Urinary symptoms experienced by patients with BPH can be classified as obstructive or irritative (see Table 1). Obstructive symptoms, sometimes referred to as “voiding symptoms,” include a decrease in the force of the urinary stream, difficulty in maintaining or initiating the stream, “dribbling” after ending the stream, or the inability to completely void the bladder. Although some obstructive symptoms can be directly correlated with restriction of urethral flow, others seem to be caused by a decrease in strength of the detrusor muscle or an increase in the excitability of the bladder muscle. Irritative symptoms of BPH also are referred to as “storage symptoms” and include dysuria, urge incontinence, urgency, nocturia, and increased frequency of urination during the day. These seem to be related to irritation of the epithelium of urethral and bladder structures.^{3,4}

The International Prostate Symptom Score (IPSS) is a validated instrument that is widely accepted for staging the severity of the disease via scoring of subjective symptoms. It also is known as the American Urological Association Urinary Symptoms Index for Prostatism (AUA Index) and is a patient-completed instrument.⁴ (See Table 2.) Score ranges equate to “mild” (0-7), “moderate” (8-19), and “severe” (20-35) symptoms. The Boyarsky Index and the Madsen-Iversen Score are additional instruments that are physician-completed.¹¹ Other instruments include the BPH Impact Index (BII), and various

health-related quality of life (QOL) measurements. Interestingly, the severity of the symptoms experienced does not always correlate directly with the measured extent of glandular enlargement or with the objective measurements utilized to monitor disease progression.

Objective measurements include uroflowmetry, such as the maximum flow rate (MFR) in milliliters of urine passed per second (also termed peak urine flow rate) and post-void residual urine (PVR). Prostate volume usually is measured by transrectal ultrasonography.^{3,4} Normal MFR ranges decrease with age. Generally, rates of less than 15 mL/s are considered to be diagnostic of a urinary flow problem; however, because lower rates often are found in older men, MFR rates alone do not indicate the need for therapy. They must be correlated with other physical findings and symptoms.¹¹

Conventional Disease Management/Treatment

“Usual” disease management can differ significantly based on the stage of the disease and the impact of symptoms on the patient’s lifestyle. The emphasis of BPH treatment has changed over the last several years from surgical intervention to medical intervention.^{2,11} The first medical approach usually is “watchful waiting”—a recognition that the problem exists. Initiation of pharmacological treatment is delayed until symptoms become more bothersome to the patient. The next step generally involves α -1 blockers (doxazosin, tamsulosin, or terazosin). These agents relax muscles of the prostate and bladder neck, thus providing symptomatic relief. They are associated with side effects including hypotension, dizziness, fatigue, and changes in sleep patterns. Another drug treatment choice is finasteride (a 5- α -reductase inhibitor), which decreases the conversion of testosterone to the more active DHT. This agent has been associated with an increased incidence of sexual dysfunction.

A final choice for treatment is surgical intervention, which generally achieves the greatest degree of efficacy. Surgical options include: localized cryotherapy or thermal therapy, transurethral incision of the prostate (TUIP), transurethral resection of the prostate (TURP), electrovaporization (modified TURP), laser surgery, or open prostatectomy. These procedures are costly and confer an increased risk of complications, such as bleeding, infection, incontinence, and sexual dysfunction.^{3,4,11,12} All of the above treatment options, with the exception of watchful waiting, are associated with adverse effects and significant cost. For these and other reasons, patients and clinicians are beginning to consider the use of alternative therapies to treat BPH.

All of the treatments that will be discussed here are phytochemical in nature and are either whole extracts from botanical sources, or single extracted or manufactured constituents originally from botanical sources. Several of these treatments have been used in other parts of the world for many years. In fact, phytochemicals are the initial treatments of choice in countries such as France and Germany. Many treatments show significant placebo effects in clinical trials; an examination of multiple BPH treatment trials provided

Alternative Medicine Alert, ISSN 1096-942X, is published monthly by American Health Consultants, 3525 Piedmont Rd., NE, Bldg. 6, Suite 400, Atlanta, GA 30305.

VICE PRESIDENT/PUBLISHER: Brenda L. Mooney.

MANAGING EDITOR: Paula L. Cousins.

GST Registration Number: R128870672.

Periodical postage paid at Atlanta, GA.

POSTMASTER: Send address changes to **Alternative Medicine Alert**, P.O. Box 740059, Atlanta, GA 30374.

Copyright © 2001 by American Health Consultants. All rights reserved. No part of this newsletter may be reproduced in any form or incorporated into any information-retrieval system without the written permission of the copyright owner.

Back Issues: \$42 per issue. Missing issues will be fulfilled by Customer Service free of charge when contacted within one month of the missing issue's date.

This is an educational publication designed to present scientific information and opinion to health professionals, to stimulate thought, and further investigation. It does not provide advice regarding medical diagnosis or treatment for any individual case. Opinions expressed are not necessarily those of this publication. Mention of products or services does not constitute endorsement. Professional counsel should be sought for specific situations. The publication is not intended for use by the layman.

AMERICAN HEALTH CONSULTANTS
THOMSON HEALTHCARE

Conflict of Interest Disclosure

In order to reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Education guidelines, physicians have reported the following relationships with companies related to the field of study covered by this CME program. Dr. Balk, Dr. Barrette, Dr. Cirigliano, Dr. deLeon, Dr. Gaster, Dr. McQueen, Dr. La Puma, Dr. Schiedermayer, Dr. Shields, and Dr. Sorrentino have no relationships with companies related to the field of study covered by this CME program.

Subscriber Information

Customer Service: 1-800-688-2421.

Customer Service E-Mail: customerservice@ahcpub.com

Editorial E-Mail: paula.cousins@ahcpub.com

World-Wide Web: http://www.ahcpub.com

Subscription Prices

United States

\$299 per year (Student/Resident rate: \$125).

Multiple Copies

1-9 additional copies: \$224 each; 10 or more copies: \$199 each

Outside the United States

\$329 per year plus GST (Student/Resident rate: \$140 plus GST).

Accreditation

American Health Consultants (AHC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

American Health Consultants designates this continuing medical education activity for up to 24 hours in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This CME activity was planned and produced in accordance with the ACCME Essentials.

Alternative Medicine Alert has been approved by the American Academy of Family Physicians as having educational content acceptable for Prescribed credit hours. Term of approval covers issues published within one year from the beginning distribution date of July 1, 2001. This volume has been approved for up to 24 Prescribed credit hours. Credit may be claimed for one year from the date of this issue.

For CME credit, add \$50.

Questions & Comments

Please call **Paula Cousins**, Managing Editor, at (816) 960-3730 between 8:30 a.m. and 4:30 p.m. ET, Monday-Friday.

estimates of this effect that ranged from 30% to 40%.² The maximal placebo effect usually is seen in the first 4-6 months of therapy.²

Pumpkin Seed

The use of pumpkin seed (*Cucurbitae peponis*) for treatment of symptoms associated with BPH has been approved by the Commission E, the German regulatory body responsible for phytomedicinals.

Pumpkin seed is theorized to act by displacing DHT from androgen receptors on human fibroblasts¹³ or by antiandrogenic/anti-inflammatory effects.¹⁴ Pumpkin seeds contain phytosterols and, therefore, may bind to androgen receptors. However, there are no human studies to support these proposed mechanisms. In addition, there have been a very limited number of clinical trials evaluating its efficacy, none of which are published in English.

Friederich et al evaluated the efficacy of 1-2 capsules of Prosta Fink Forte, a brand-name standardized extract, in the treatment of 2,245 patients who were classified as "Alken stage I or II" (this scale has not been equated to other standardized scales).¹⁵ The trial abstract reports that the results demonstrated a decrease in IPSS and quality of life improvement.

The average daily dose is 10 grams of the ground seeds in either single or divided doses.^{14,16,17} No adverse reactions or interactions with other drugs have been reported with the use of pumpkin seeds.¹⁴⁻¹⁷

β -Sitosterol

β -sitosterol is a dietary supplement used for cholesterol level modification as well as for the treatment of BPH. It is one of the principal phytosterols in pygeum, another supplement used to treat BPH symptoms.

The mechanism of action of the sitosterols is not well understood. Multiple mechanisms have been proposed and include antiandrogenic and antiestrogenic effects, inhibition of prostaglandin synthesis, and anti-inflammatory action.^{12,16}

A limited number of trials have evaluated the efficacy of β -sitosterol. The β -sitosterol study group examined 200 patients and evaluated the efficacy of Harzol[®] brand β -sitosterol (extracted from African star grass [*Hypoxis rooperi*]) 20 mg three times per day for six months to treat the symptoms of BPH.¹⁸ The researchers noted a significant decrease in modified Boyarsky score (6.7 in the treatment group vs. 2.1 in the placebo group) after four weeks of intervention. The study also showed statistically significant improvement in all of the following parameters in the treatment and placebo groups, respectively: IPSS (7.4 point vs. 2.1 point reduction), QOL (1.4 vs. 0.2 reduction), MFR (5.2 mL/s vs. 1.1 mL/s increase), median flow rate (3.0 mL/s vs. 0.3 mL/s increase), voiding time (15.5 s reduction vs. 2.8 s increase), and RUV (35.4 mL vs. 11.6 mL reduction). Those participants who continued in the β -sitosterol treatment group maintained the improvement in all parameters, but did not demonstrate further improvement during an 18-month follow-up to the study.¹⁹

Table 1

Symptoms of benign prostatic hyperplasia

Obstructive

- Decreased force of urine stream
- Hesitancy or difficulty in initiating stream
- Straining to urinate
- Dribbling after urination
- Incomplete emptying of bladder
- Urinary retention

Irritative

- Increased urination frequency
- Nocturia
- Dysuria
- Urgency
- Urge incontinence

A separate trial compared the efficacy of Azuprostat[®] 130 mg daily and placebo over a six-month period in 177 patients with symptomatic BPH.²⁰ The treatment group showed a statistically significant decrease in IPSS scores in favor of the treatment group compared to placebo, 8.2 vs. 2.8, as well as marked decrease in RUV, 59% vs. 7%, respectively. The most marked changes occurred during the first month of therapy, and then additional improvements were demonstrated more slowly throughout the course of treatment.

Very few adverse effects have been reported; the most common side effect is GI disturbance. Two incidents of sexual dysfunction have been reported.¹⁸ The daily dose range is 60-130 mg of β -sitosterol. Theoretically, interactions could include an additive effect with antihyperlipidemics. For that reason, firm adherence to scheduled cholesterol monitoring is recommended for patients on lipid-lowering medications.

Rye Grass

Rye grass pollen extract is a supplement traditionally used for the relief of BPH symptoms. It is believed to work by multiple mechanisms that include antiandrogenic effects, increased bladder muscle control, relaxation of urethral smooth muscle,²¹ and inhibition of prostaglandin and leukotriene synthesis.²²

Several studies have evaluated the efficacy of a particular brand of extract called Cernilton[®]. One randomized, double-blind, clinical trial evaluated Cernilton 126 mg twice daily for six months vs. placebo in 60 patients awaiting operative treatment for outflow obstruction.²³ The results indicated statistically significant improvement in symptoms of nocturia and incomplete emptying. The study also showed a statistically significant decrease in anteroposterior diameter (18.2% in the Cernilton group vs. 4.6% in the placebo group) and a decrease in residual urine volume (101.9 \pm 87.3 mL vs. 113.4 \pm 87.3 mL). The authors also reported no adverse effects in the treatment group.

Table 2

American Urological Association (AUA) Urinary Symptom Index for Prostatism

| Symptom | Score | | | | | |
|--|------------|----------------|--------------|--------------|--------------|---------------|
| | Not at All | < 1 in 5 Times | < ½ the Time | = ½ the Time | > ½ the Time | Almost Always |
| 1. Over the past month or so, how often have you had a sensation of not emptying your bladder completely after you finished urinating? | 0 | 1 | 2 | 3 | 4 | 5 |
| 2. Over the past month or so, how often have you had to urinate again less than two hours after you finished urinating? | 0 | 1 | 2 | 3 | 4 | 5 |
| 3. Over the past month or so, how often have you found you stopped and started several times when you urinated? | 0 | 1 | 2 | 3 | 4 | 5 |
| 4. Over the past month or so, how often have you found it difficult to postpone urination? | 0 | 1 | 2 | 3 | 4 | 5 |
| 5. Over the past month or so, how often have you had a weak urinary stream? | 0 | 1 | 2 | 3 | 4 | 5 |
| 6. Over the past month or so, how often have you had to push or strain to begin urination? | 0 | 1 | 2 | 3 | 4 | 5 |
| 7. Over the past month or so, how many times did you most typically get up to urinate from the time you went to bed at night until the time you got up in the morning? | 0 times | 1 time | 2 times | 3 times | 4 times | 5 times |

Interpretation of AUA Symptom Index AUA Symptom Score = Sum of Questions 1-7 = _____

Mild prostatism ≤ 7

Moderate prostatism 8-18

Severe prostatism > 18

Highest possible score = 35

Adapted from: Barry M, et al. The American Urological Association symptom index for benign prostatic hyperplasia. *J Urol* 1992;148:1549-1557.

One study in 159 patients compared Cernilton to Paraprost[®], another product used for BPH symptoms that is a mixture of the amino acids L-glutamine, L-arginine, and glycine.²⁴ The study noted significant improvements in the Cernilton group in respect to RUV, MFR, and prostate weight. The investigators determined that the intervention was “moderately effective” in 49.1% of the Cernilton patients as compared to 41.2% in Paraprost group. There were no adverse effects or clinical abnormalities noted.

Another study evaluating Cernilton 126 mg twice daily for 12 weeks in 79 men with mild-to-moderate symptomatic BPH concluded that the rye grass pollen extract caused improvement from baseline in all subjective symptoms measured as well as in flow rate and residual urine volume.²⁵ The symptoms examined were urgency/discomfort, dysuria, nocturia, incomplete emptying, prolonged voiding, delayed voiding, intermittency, and post-void dribbling. One major limitation to the validity of the study was the lack of a control group.

A more recent study evaluated the efficacy of Cernilton compared to Tadenan[®] in 89 patients (ages 50-68 years) with Stage I BPH.²² Tadenan is a *Pygeum africanum* extract standardized to 14% triterpenes and 0.5% n-docosanol. The results indicated that both products provided increased flow rate and decreased urine volume. In addition, both treatment groups noted an improvement in subjective symptom scores. However, methodological limitations of the study limit its usefulness in clinical decision-making.

Additional studies evaluating the efficacy of Cernilton in the treatment of BPH have reported significant improvements in objective as well as subjective parameters; however, these studies have not been published in English and, therefore, the quality of methodology could not be evaluated.^{26,27}

Clinical trials have reported no adverse effects associated with rye grass pollen extract therapy.²⁴⁻²⁷ The typical dose of extract studied in trials is 126 mg twice or three times daily for 3-6 months. There are no known interactions with

Table 3
Clinical trials of alternative therapies for benign prostatic hyperplasia

| Supplement | Dose | Urodynamics | Symptoms | Prostate Size | PSA | Nocturia | Side Effects | Efficacy Evidence |
|--|--------------------|-------------|----------|---------------|-----|----------|---|-------------------|
| Pygeum (14% triterpenes and 0.5% n-docosanol) | 75-200 mg/d | + | + | — | U | + | GI discomfort, constipation, nausea, diarrhea | Good |
| Saw Palmetto (> 85% fatty acids and sterol) | 160 mg bid | + | + | — | — | + | GI discomfort, headache, dizziness, impotence (with high doses) | Good |
| Stinging Nettle (hydroalcoholic root extract) | 600-1,200 mg/d | + | + | — | U | + | GI distress, skin reactions, hyperhidrosis | Fair |
| Rye Grass Pollen Cernilton® | 126 mg bid or tid | + | + | + | U | + | None reported | Fair |
| β-Sitosterol | 60-130 mg QD | + | + | — | U | U | GI upset, nausea, diarrhea | Fair |
| Pumpkin Seed | 10 g/d ground seed | U | + | U | U | U | None reported | Poor |

Legend: + = positive effect; — = no effect; U = unknown effect

Efficacy Evidence
 Excellent: Several well-designed, controlled human trials with minimal limitations
 Good: Controlled human trials, with moderate design limitations
 Fair: Controlled human trials, with major design limitations or very small populations
 Poor: Few uncontrolled human studies

prescription medications. Recommended monitoring is limited to that associated with the disease state.

Stinging Nettle Root

The root of the stinging nettle (*Urtica dioica*) contains polysaccharides which are believed to be responsible for its anti-inflammatory effects. Unidentified components present in certain aqueous, but not lipophilic, extracts reduce the binding of sex hormone binding globulin (SHBG) to prostatic membrane receptors²⁸ and inhibit 5- α -reductase and prostatic aromatase.¹³

Although four double-blind, placebo-controlled studies have been performed, the quality of the evidence could not be analyzed for this review, because none of the trials have been published in English. Tertiary sources have summarized the results of the trials, which included a total of 210 patients. The most recent trial reported a significantly larger decrease in the IPSS for the nettle root group, but differences in MFR, PVR, and QOL score were not significant. Other trials reported an improvement in symptoms, as well as significant improvements in urinary output and MFR and a reduction of SHBG.¹³

An observational study of 67 patients with BPH, ages 53-87 years, was conducted using an aqueous alcohol extract of *Urtica dioica* and *Urtica urens* (dog nettle) roots for six

months.²⁹ The investigators documented clinically significant reductions from baseline in episodes of nocturia and corresponding decreases in post-void bladder volume. Prostate volume, as measured by ultrasound, was unchanged.

Stinging nettle root is well tolerated. A six-month study in 4,087 patients reported very few adverse events.¹³ These were GI distress, allergic skin reactions, and hyperhidrosis. There are no known drug interactions with stinging nettle root, although there is a theoretical interaction with finasteride, based on the possibility of a clinically significant level of 5- α -reductase inhibition. Until more is known, concomitant use with finasteride should be avoided or carefully monitored.

Doses of stinging nettle root used in the majority of clinical trials ranged from 600 to 1,200 mg/d of hydroalcoholic root extract. Patients who choose to use stinging nettle need to be aware that products are available that use the leaves and other above ground parts of the plant; these products have different chemical components and indications and cannot be used interchangeably.¹⁴

Pygeum africanum

The lipid-soluble constituents within the bark of the pygeum tree are the most pharmacologically active. The bark contains approximately 14% triterpenes; ferulic acid esters,

such as n-docosanol and n-tetracosanol; and several phytosterols.^{13,30,31} The anti-inflammatory activity associated with pygeum is due primarily to the action of the triterpenes, which inhibit enzymes implicated in connective tissue deterioration.^{13,32} Prostaglandin formation within the prostate also is inhibited.³³ The phytosterol components inhibit prostaglandin synthesis and compete with precursors of androgens.¹³ N-docosanol, specifically, has been demonstrated to decrease levels of testosterone, luteinizing hormone (LH), and prolactin in animal studies,³¹ although one human study examining testosterone, follicle-stimulating hormone, LH, and estrogens did not find significant changes.³⁴ Pygeum also has an effect on glandular epithelium, causing “normalization” of histological changes. Inhibition of fibroblast proliferation and increases in prostatic secretions have been noted, as well as estrogenic and antiestrogenic activity.³⁵ The slight decrease in prolactin (which stimulates intraprostatic DHT synthesis and testosterone uptake) and possibly in testosterone; a decrease in proliferation of fibroblasts within the gland;^{36,37} and a reduction in the excitability of the detrusor muscle³⁷ all contribute to alleviation of obstructive symptoms. Irritative symptoms may be relieved more by the increase in prostatic secretions. Although pygeum does inhibit 5- α -reductase, as well as the androgen receptors’ binding of DHT, these actions are so minimal they probably are clinically insignificant.³⁴

Although 46 investigations of pygeum extract have been conducted to date, only 11 have been placebo-controlled trials. A review of available trials, completed in 1995, concluded that pygeum extract did provide some benefit for both objective and subjective BPH symptoms and should be investigated further in comparison to standard pharmacological treatments.³⁷ The 43 trials covered in the analysis included a total of 2,262 patients.

Of the placebo-controlled studies, the largest to date (n = 263) was published in German by Barlet et al in 1990.³⁸ A moderately detailed description of the trial based on an English translation was published in 2000.³⁹ Results of this trial showed statistically significant improvement compared to placebo for symptoms of daytime and nighttime micturations, residual urine volume (24.5% and 3.5% reduction, respectively), urine volume (12% and 3.2% increase, respectively) and MFR (17.2 and 4.3% increase, respectively), with no change in the prostate volume.

A more recent meta-analysis of pygeum trials was published in 2000.⁴⁰ Eighteen trials met the inclusion criteria for the meta-analysis and presented the experiences of 1,562 patients. Thirteen trials were placebo-controlled and five were compared to other treatments such as NSAIDs or other herbal products. No comparisons to finasteride or α -blockers have been conducted. Twelve of the 13 placebo-controlled trials reported more improvement in outcome measures for the pygeum groups and one did not find any difference in outcomes. Based on the effect size calculated for each of the trials, an overall effect size was estimated using six trials of pygeum (n = 474) that were judged by the authors to be sufficient for result pooling. The overall summary effect size of -0.8 (95% CI, -1.4 to -0.3) calculated by the authors is equiva-

lent to an improvement that is both large and statistically significant. A summary effect size for improvement in nocturia was calculated separately and also was -0.8 (95% CI of -1.4 to -0.1), a moderate to large effect. The authors concluded that overall results of the analysis support improvements in urinary symptoms, peak urine flow, and nocturia that are moderate and statistically significant and that *Pygeum africanum* extracts may be an effective short-term treatment option for patients with BPH symptoms.

Pygeum is well tolerated. Adverse effects reported in studies are mild and include nausea, constipation, diarrhea, and gastrointestinal discomfort.^{37,38,40} No interactions with any pharmaceutical agents have been identified or reported, although the possibility of additive hormonal effects should be kept in mind.

Doses used in clinical trials have ranged from 75 to 200 mg/d. One trial compared a 100 mg/d dosage given once daily or in two divided doses and found no difference in outcome.⁴¹ The extract should be standardized to contain 14% triterpenes and 0.5% n-docosanol.

Saw Palmetto

The lipophilic extract of *Serenoa repens* (also known as *Sabal serrulata*) inhibits 5- α -reductase activity, theoretically decreasing the amount of DHT produced from testosterone. Although finasteride more specifically inhibits type two 5- α -reductase, *Serenoa repens* (saw palmetto) inhibits both types one and two.⁴² The extent and significance of this activity in vivo is not completely understood, and measurements of the reductase activity are not always significantly decreased.⁴³ In addition, saw palmetto may decrease prolactin and have anti-inflammatory activity, as well as inhibit fibroblast and epidermal growth factors. Although antiestrogenic effects may exist, this action has not been well described.

Saw palmetto is the most investigated of all natural product therapies used for the treatment of BPH. A systematic review of saw palmetto trials was published in 1998.⁴⁴ The investigators analyzed 18 of the 24 trials located in an exhaustive literature search. Analysis revealed 24–28% improvements in nocturia, MFR, mean urine flow, and “urinary tract symptoms” compared to placebo. Improvements were similar when compared to finasteride. The authors concluded that saw palmetto extracts do improve BPH symptoms and that improvements are similar to those experienced with finasteride treatments; however, fewer adverse effects were reported in the saw palmetto groups.

One of the placebo-controlled studies is of particular interest because of the investigators’ attempt to reduce the influence of the placebo effect (i.e., BPH symptoms are known to be associated with placebo response rates of 30–40% or more in clinical trials²). Descotes et al designed a trial in which all patients with a 30% or greater improvement in symptom scores during a 30-day placebo run-in period were excluded from the study population. The remaining patients (n = 176) were randomized to receive placebo or a standardized saw palmetto extract 160 mg (Permixon®) twice daily for 30 days. Results included a significantly greater increase in MFR in the

Permixon group (28.9% vs. 8.5% for Permixon and placebo, respectively). There also was a significant difference between groups in the decrease of nocturnal urinations (-32.5% vs. -17.7% for Permixon and placebo, respectively). Despite the differences in these more objective parameters, however, the patient-based and physician-based global assessments of efficacy did not reveal significant differences, although they did favor Permixon. The investigators concluded that the overall clinical significance of Permixon treatment probably was less than what might be indicated by the statistically significant differences between treatment groups.⁴⁵

A three-year observational study of the IDS 89 extract of saw palmetto in 435 patients noted an increase in MFR of 6.1 mL/s (13.4 mL/s to 19.5 mL/s) and a 50% reduction in RUV (64 ± 41 mL to 32 ± 36 mL). Nocturia resolved or improved in 73.3% of patients. According to the Boyarsky scale, 53-80% of patients were classified as symptom-free or improved. The investigators noted that the deterioration rate at three years for the 315 patients who completed the study was significantly lower than would be expected in BPH patients not receiving pharmacological or surgical treatment.⁴⁶

Additionally, the standardized saw palmetto lipophilic extract, Permixon, has been compared to the 5- α -reductase inhibitor finasteride.⁴⁷ Patients (n = 1,098) were randomized to receive Permixon 160 mg twice daily or finasteride 5 mg once daily for 26 weeks. The primary outcome measure was improvement in the IPSS. Assessments of QOL, sexual function, prostate-specific antigen (PSA), urodynamics, and prostate volume also were performed. The IPSS decreased by 37% and 39% and MFR increased by 25% and 30% in the Permixon and finasteride groups, respectively. QOL improved approximately 40% in both groups. Differences were noted between the Permixon and finasteride groups for prostate volume, which decreased 6% vs. 18%, respectively, and for PSA, which was unaffected by Permixon, but decreased 41% in the finasteride group. Adverse event reports indicated that sexual function was less affected by Permixon than by finasteride.

Saw palmetto generally is well tolerated. A few reports include adverse events of nausea, headache, dizziness, dysuria, and GI discomfort. A three-year study in 435 patients reported mild adverse events in 34 patients.¹³ High doses have been associated with impotence and decreased libido. Although no interactions with pharmaceutical agents have been specifically identified, recommendations to avoid use in conjunction with hormonal or antihormonal therapies seem sound, based on the known pharmacological actions.

Saw palmetto products should be standardized to contain 85% or more fatty acids and sterols. The dose is 160 mg twice daily and may be taken with meals if GI upset occurs.

Conclusions

The most important contraindication to any alternative or complementary therapy is lack of a medical diagnosis. As with any BPH therapy, the possibility of prostate cancer must be eliminated before patients begin any symptomatic treatment.

Monitoring of patients taking any of the alternative treatments discussed should be the same as for any BPH patient: digital rectal exam to observe for increase in prostate size, a scored symptom questionnaire, and a regular serum PSA. An increase in or exacerbation of symptoms may indicate the necessity for uroflowmetry studies, urine culture, or biopsy. In addition, an inquiry into any possible side effects should be a part of any regular clinic visit.

Because BPH usually is a long-term, slowly progressing disease state whose standard treatment often includes "watchful waiting," the use of alternative therapies for symptom reduction can be very appropriate. Unfortunately, those products tested in BPH clinical trials are not widely accessible in the United States. Therefore, successful treatment requires products standardized to the same component percentages as the tested products, good patient education to ensure safety, and reasonable patient and physician expectations. ❖

Dr. McQueen is Assistant Director, Drug Information Center, and Clinical Assistant Professor, Division of Pharmacy Practice, and Shields is Fellow, Natural Product Research, University of Missouri-Kansas City School of Pharmacy.

References

1. United States Agency for Health Care Policy and Research. *Benign Prostatic Hyperplasia: Diagnosis and Treatment*. Rockville, MD; 1995:11-13.
2. Hansen BJ, et al. Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. The ALFECH Study Group. *Scand J Urol Nephrol* 1996;30: 374-377.
3. Brendler CB, Steinberg GD. Diseases of the Prostate. In: Bennett JC, et al, eds. *Cecil Textbook of Medicine*. 19th ed. Philadelphia, PA: WB Saunders Co.; 1996:1351-1354.
4. Thompson JF. Geriatric Urologic Disorders. In: Koda-Kimble MK, et al, eds. *Applied Therapeutics*. Philadelphia, PA: Wolters Kluwer Co.; 2001:99-15 to 99-24.
5. Cotran RS, et al, eds. *Robbins Pathologic Basis of Disease*. 5th ed. Philadelphia, PA: WB Saunders; 1994:1025-1026.
6. Hiramatsu M, et al. Immunolocalization of oestrogen and progesterone receptors in prostatic hyperplasia and carcinoma. *Histopathology* 1996;28:163-168.
7. Lagiou P, et al. Diet and benign prostatic hyperplasia: A study in Greece. *Urology* 1999;54:284-290.
8. Sciarra F, Toscano V. Role of estrogens in human benign prostatic hyperplasia [abstract]. *Arch Androl* 2000;44:213-220.
9. Araki H, et al. High-risk group for benign prostatic hypertrophy. *Prostate* 1983;4:253-264.
10. Chyou PH, et al. A prospective study of alcohol, diet, and other lifestyle factors in relation to obstructive uropathy. *Prostate* 1993;22:253-264.
11. Nuffield Institute for Health, University of Leeds and NHS Centre for Reviews and Dissemination, University of York. *Effective Healthcare: Benign Prostatic Hyperplasia*. Leeds, UK; 1995.

12. Chacon A, Monga M. Medical management of benign prostatic hyperplasia. *Geriatr Nephrol Urol* 1999;9:39-48.
13. Schulz V, et al. *Rational Phytotherapy*. 3rd ed. Berlin: Springer-Verlag; 1997:232-234.
14. Blumenthal M, et al ed. *Herbal Medicine: Expanded Commission German E Monographs*. Newton, MA: Integrative Medicine Communications; 2000.
15. Friederich M, et al. Prosta Fink Forte capsules in the treatment of benign prostatic hyperplasia. Multicentric surveillance study in 2245 patients [in German]. *Forsch Komplementarmed Klass Naturheilkd* 2000;7:200-204.
16. Jellin J, ed. *The Natural Medicines Comprehensive Database*. Stockton, CA: Therapeutic Research; 2001. Available at: <http://www.naturaldatabase.com>. Accessed September 2001.
17. Fleming T, et al, eds. *PDR for Herbal Medicines*. 2nd ed. Montvale, NJ: Medical Economics Co.; 2000.
18. Berges RR, et al. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. *Lancet* 1995;345:1529-1532.
19. Berges RR, et al. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: An 18 month follow-up. *BJU Int* 2000;85:842-846.
20. Klippel KF, et al. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study Group. *Br J Urol* 1997;80:427-432.
21. MacDonald R, et al. A systemic review of Cernilton for the treatment of benign prostatic hyperplasia. *BJU Int* 2000;85: 836-841.
22. Dutkiewicz S. Usefulness of Cernilton in the treatment of benign prostatic hyperplasia. *Int Urol Nephrol* 1996;28:49-53.
23. Buck AC, et al. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with pollen extract, Cernilton. *Br J Urol* 1990;66:398-404.
24. Maekawa M, et al. Clinical evaluation of Cernilton on benign prostatic hypertrophy—a multiple center double-blind study with Paraprost [English abstract]. *Hinyokika Kyo* 1990;36: 495-516.
25. Yasumoto R, et al. Clinical evaluation of long-term treatment using cerniltin pollen extract in patients with benign prostatic hyperplasia. *Clin Ther* 1995;17:82-87.
26. Hayashi J, et al. Clinical evaluation of Cernilton in benign prostatic hypertrophy [English abstract]. *Hinyokika Kyo* 1986;32: 135-141.
27. Horii A, et al. Clinical evaluation of cernilton in benign prostatic hypertrophy [English abstract]. *Hinyokika Kyo* 1985;31: 739-746.
28. Hryb DJ, et al. The effect of extracts of the roots of the stinging nettle (*Urtica dioica*) on the interaction of SHBG with its receptor on human prostatic membranes. *Planta Med* 1995; 61:31-32.
29. Belaiche P, Lievoux O. Clinical studies on the palliative treatment of prostatic adenoma with extract of *Urtica* root. *Phytother Res* 1991;5:267-269.
30. Foster S, Tyler VE. *Tyler's Honest Herbal*. New York: The Haworth Herbal Press; 1999:307.
31. DerMarderosian A, ed. Pygeum monograph, 1998. In: *Review of Natural Products*. St. Louis, MO: Facts and Comparisons; 2000.
32. Paubert-Braquet M, et al. Effect of *Pygeum africanum* extract on A23187-stimulated production of lipoxygenase metabolites from human polymorphonuclear cells. *J Lipid Mediat Cell Signal* 1994;9:285-290.
33. Marcoli M. Anti-inflammatory and antiedemigenic activity of extract of *Pygeum africanum*. *New Trends Androl Sci* 1985; 1:89.
34. McCutcheon AR. Pygeum. In: Chandler F, ed. *Herbs: Everyday Reference for Health Professionals*. Ottawa: Canadian Pharmacists Association; 2000:176-178.
35. Mathé G, et al. The so-called phyto-estrogenic action of *Pygeum africanum* extract. *Biomed Pharmacother* 1995;49: 339-340.
36. Yablonsky F, et al. Antiproliferative effect of *Pygeum africanum* extract on rat prostatic fibroblasts. *J Urol* 1997;157: 2381-2387.
37. Andro MC, Riffaud JP. *Pygeum africanum* extract for the treatment of patients with benign prostatic hyperplasia. A review of 25 years of published experience. *Curr Ther Res* 1995;56:796-817.
38. Barlet A, et al. Efficacy of *Pygeum africanum* extract in the medical therapy of urination disorders due to benign prostatic hyperplasia: Evaluation of objective and subjective parameters. A placebo-controlled double-blind multicenter study [in German]. *Wien Klin Wochenschr* 1990;102:667-673.
39. McQueen CE, Bryant PJ. Pygeum. *Am J Health Syst Pharm* 2001;58:120-123.
40. Ishani A, et al. *Pygeum africanum* for the treatment of patients with benign prostatic hyperplasia: A systematic review and quantitative meta-analysis. *Am J Med* 2000;109:654-664.
41. Chatelain C, et al. Comparison of once and twice daily dosage forms of *Pygeum africanum* extract in patients with benign prostatic hyperplasia: A randomized, double-blind study, with long-term open label extension. *Urology* 1999;54:473-478.
42. Iehlé C, et al. Human prostatic steroid 5 alpha-reductase isoforms—a comparative study of selective inhibitors. *J Steroid Biochem Mol Biol* 1995;54:273-279.
43. Strauch G, et al. Comparison of finasteride (Proscar) and *Serenoa repens* (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. *Eur Urol* 1994;26:247-252.
44. Wilt T, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review. *JAMA* 1998;280: 1604-1609.
45. Descotes JL, et al. Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. *Clin Drug Invest* 1995;9: 291-297.
46. Bach D, Ebeling L. Long-term drug treatment of benign prostatic hyperplasia—results of a prospective 3-year multi-center study using Sabal extract IDS 89. *Phytomedicine* 1996;3: 105-111.
47. Carraro JC, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients. *Prostate* 1996;29:231-240.